Skip to main content
TipRanks
Go Ultimate75% OFF

Astec Lifesciences Limited (ASTEC) AI Stock Analysis

1 Followers
IN:ASTEC

Astec Lifesciences Limited

(NSE:ASTEC)

Select Model
Rating:39Underperform
Price Target:INR 500.00▼(-9.76% Downside)
Action:downgraded
Date:11/11/26

The overall stock score is heavily weighed down by deep operational struggles and bearish market sentiment. Massive cash burn and an inability to generate positive earnings are the most significant risks, which are further compounded by strong negative technical momentum and a lack of valuation support.

Positive Factors
Crop-protection business modelAstec operates across technical ingredients, intermediates and selected formulations used in insecticides, herbicides and fungicides. This positions the company within essential crop-protection supply chains and provides exposure to recurring agricultural demand across both domestic and international markets.
Negative Factors
Sustained operating lossesThe shift from solid profits to sizable operating and net losses across FY24–FY26 signals a material deterioration in earnings power. Continued negative profitability can weaken retained capital, reduce funding flexibility, and make the FY26 revenue recovery less durable unless margins improve.

Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:ASTEC-11.52%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 12.30B
Dividend Yield
―
Average Volume (3M)
11.82K
Price to Earnings (P/E)
-15.5
Beta (1Y)
1.08
Revenue Growth
16.06%
EPS Growth
36.97%
Country
India
Employees
471
Sector
General
Sector Strength
55
Industry
Agricultural Inputs

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the co...

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences is navigating severe financial distress characterized by chronic unprofitability and accelerating cash burn, with operating cash flow plunging to negative 1.12 billion. While the balance sheet saw vital deleveraging and a modest top-line recovery to 4.48 billion, core fundamentals remain deeply weak.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue4.39B4.48B3.81B4.58B6.28B6.77B
Gross Profit686.74M419.01M-685.16M1.33B2.27B2.86B
EBITDA-46.13M-15.49M-662.07M-2.69M893.14M1.65B
Net Income-795.77M-809.17M-1.35B-469.30M255.65M898.59M
Balance Sheet
Total Assets7.94B9.42B8.81B9.75B9.79B8.97B
Cash, Cash Equivalents and Short-Term Investments22.82M122.51M8.55M16.47M27.54M33.44M
Total Debt3.31B4.49B5.55B4.94B3.41B2.79B
Total Liabilities4.59B5.51B6.46B6.05B5.60B5.00B
Stockholders Equity3.35B3.91B2.35B3.69B4.19B3.96B
Cash Flow
Free Cash Flow0-1.18B-302.20M-1.25B-426.03M-803.74M
Operating Cash Flow0-1.13B-83.99M102.21M746.56M236.04M
Investing Cash Flow0-49.07M-152.30M-1.35B-1.13B-1.04B
Financing Cash Flow01.27B237.33M1.25B377.70M804.77M

Astec Lifesciences Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price554.10

Price Trends

50DMA659.21Negative
100DMA656.67Negative
200DMA660.78Negative

Market Momentum

MACD-40.01Positive
RSI35.86Neutral
STOCH41.06Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 554.10 is below the 20-day moving average (MA) of 606.23, below the 50-day MA of 659.21, and below the 200-day MA of 660.78, indicating a bearish trend. The MACD of -40.01 indicates Positive momentum. The RSI at 35.86 is Neutral, neither overbought nor oversold. The STOCH value of 41.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ASTEC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:DHANUKAIN:DHANUKA73OutperformINR 40.27B14.56―0.22%-0.06%0.75%
IN:SHARDACROPIN:SHARDACROP71OutperformINR 65.69B10.22―2.06%17.28%42.45%
IN:BHARATRASIN:BHARATRAS67NeutralINR 17.52B7.75―0.05%-5.17%4.24%
IN:INSECTICIDIN:INSECTICID66NeutralINR 15.74B12.58―0.92%1.26%-16.43%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:IPLIN:IPL55NeutralINR 13.73B14.38―0.63%2.89%-9.47%
IN:ASTECIN:ASTEC39UnderperformINR 12.33B-15.54――16.06%36.97%

* General Sector Average

Performance Comparison

-50%0%50%IN:ASTECIN:BHARATRASIN:DHANUKAIN:INSECTICIDIN:IPLIN:SHARDACROPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ASTEC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ASTECAstec Lifesciences Limited554.10-96.30-14.81%
IN:BHARATRASBharat Rasayan Limited981.00-1563.79-61.45%
IN:DHANUKADhanuka Agritech Limited895.40-339.02-27.46%
IN:INSECTICIDInsecticides (India) Limited534.85-141.22-20.89%
IN:IPLIndia Pesticides Ltd.117.70-59.00-33.39%
IN:SHARDACROPSharda Cropchem Ltd.721.90-37.53-4.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026